

PHARMACEUTICAL 2022



AVADEL PHARMACEUTICALS PLC Rank 341 of 466







PHARMACEUTICAL 2022

AVADEL PHARMACEUTICALS PLC Rank 341 of 466



The relative strengths and weaknesses of AVADEL PHARMACEUTICALS PLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AVADEL PHARMACEUTICALS PLC compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 24% points. The greatest weakness of AVADEL PHARMACEUTICALS PLC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 169% points.

The company's Economic Capital Ratio, given in the ranking table, is 27%, being 51% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	192,490
Cost of Goods Sold	0
Intangible Assets	16,836
Liabilities, Current	21,000
Liabilities, Non-Current	148,021
Other Assets	37,654
Other Compr. Net Income	-2,889
Other Expenses	-5,927
Other Liabilities	0
Other Net Income	2,343
Other Revenues	0
Property and Equipment	285
Research and Development	17,104
Selling, General and Administrative Expense	68,495

Output Variable	Value in 1000 USD
Assets	247,265
Liabilities	169,021
Expenses	79,672
Revenues	0
Stockholders Equity	78,244
Net Income	-77,329
Comprehensive Net Income	-78,774
Economic Capital Ratio	27%

